Market research
1521.HK Frontage Holdings Corporation
HK HKD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 37.25
- Analyst target
- 1.1134
- Dividend yield
- Not available
- Beta
- 0.22
Profile
Instrument facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG3679P1019
- Market cap
- 3B
- P/E ratio
- 37.25
- Analyst target
- 1.1134
- Dividend yield
- Not available
- Beta
- 0.22
About
About Frontage Holdings Corporation
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Research context
Frontage Holdings Corporation appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1521.HK discussion.
5 years, 7 months ago
Frontage Holdings Corporation is currently in a long term uptrend where the price is trading 42.4% above its 200 day moving average.
From a valuation standpoint, the stock is 90.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.2.
Frontage Holdings Corporation's total revenue sank by 0.1% to $51M since the same quarter in the previous year.
Its net income has dropped by 51.8% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 170.7% to $6M since the same quarter in the previous year.
Based on the above factors, Frontage Holdings Corporation gets an overall score of 3/5.